Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of
bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC). This
study will be activated at the UT Southwestern Medical Center, comprised of The Harold C.
Simmons Comprehensive Cancer Center, UT Southwestern Hospitals-St. Paul and Parkland Memorial
Hospital System. Advanced HCC is defined as disease that is not amenable to surgical
resection or orthotopic liver transplantation or is metastatic in nature.